nach oben

Drugs

Erschienen in:

01.05.2015 | R&D Insight Report

Isavuconazonium: First Global Approval

verfasst von: Paul L. McCormack

Erschienen in: Drugs | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Isavuconazonium (Cresemba^®) is a water-soluble prodrug of the triazole antifungal isavuconazole (BAL 4815), a 14-α-demethylase inhibitor, under development by Basilea Pharmaceutica International Ltd and Astellas Pharma Inc. Isavuconazonium, in both its intravenous and oral formulations, was approved for the treatment of invasive aspergillosis and invasive mucormycosis (formerly termed zygomycosis) in the US in March 2015. Isavuconazonium is under regulatory review in the EU for invasive aspergillosis and mucormycosis. It is also under phase III development worldwide for the treatment of invasive candidiasis and candidaemia. This article summarizes the milestones in the development of isavuconazonium leading to the first approval for invasive aspergillosis and mucormycosis.

Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163–74.PubMedCentralPubMed

US Food and Drug Administration. FDA approves new antifungal drug Cresemba. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm437106.htm. Accessed 12 Mar 2015.

US Food and Drug Administration. Cresemba (isavuconazonium sulfate): US prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf. Accessed 18 Mar 2015.

Astellas Pharma US Inc. FDA grants Astellas Qualified Infectious Disease Product designation for isavuconazole for the treatment of invasive candidiasis (media release). 2014. http://newsroom.astellas.us/2014-07-16-FDA-Grants-Astellas-Qualified-Infectious-Disease-Product-Designation-for-Isavuconazole-for-the-Treatment-of-Invasive-Candidiasis.

European Medicines Agency. Public summary of opinion on orphan designation: isavuconazonium sulfate for the treatment of invasive aspergillosis. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2014/07/WC500169890.pdf. Accessed 18 Mar 2015.

European Medicines Agency. Public summary of opinion on orphan designation: isavuconazonium sulfate for the treatment of mucormycosis. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2014/07/WC500169714.pdf. Accessed 18 Mar 2015.

Basilea Pharmaceutica. Basilea announces global partnership with Astellas for its antifungal isavuconazole (media release). 2010. http://www.basilea.com/News-and-Media/Basilea-announces-global-partnership-with-Astellas-for-its-antifungal-isavuconazole/343.

Basilea Pharmaceutica. Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America (media release). 2014. http://www.basilea.com/News-and-Media/Basilea-swaps-its-isavuconazole-North-American-co-promote-rights-for-full-isavuconazole-rights-outside-of-North-America/c54f2a5d-f004-4aed-2d5c-d5f26ba841ae.

Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170(5):291–313.CrossRefPubMed

10.

Lepak AJ, Marchillo K, Vanhecker J, et al. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and CYP51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2013;57(12):6284–9.CrossRefPubMedCentralPubMed

11.

Lepak AJ, Marchillo K, VanHecker J, et al. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother. 2013;57(11):5642–8.CrossRefPubMedCentralPubMed

12.

Majithiya J, Sharp A, Parmar A, et al. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother. 2009;63(1):161–6.CrossRefPubMedCentralPubMed

13.

Warn PA, Sharp A, Parmar A, et al. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother. 2009;53(8):3453–61.CrossRefPubMedCentralPubMed

14.

Luo G, Gebremariam T, Lee H, et al. Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother. 2014;58(4):2450–3.CrossRefPubMedCentralPubMed

15.

Schmitt-Hoffmann A, Roos B, Maares J, et al. Mulitple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):286–93.CrossRefPubMedCentralPubMed

16.

Schmitt-Hoffmann A, Roos B, Spickermann J, et al. No relevant food effects in man on isavuconazole oral pharmacokinetics preliminary data (abstract no. A-008). In: 48th interscience conference on antimicrobial agents and chemotherapy/Infectious Diseases Society of America 46th annual meeting. 2008.

17.

Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100. and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):279–85.CrossRefPubMedCentralPubMed

18.

Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother. 2009;53(11):4885–90.CrossRefPubMedCentralPubMed

19.

Yamazaki T, Pearlman H, Kowalski DL, et al. Effect of multiple doses of ketoconazole on the pharmacokinetics of isavuconazole in healthy subjects (abstract no. A-695). In: 54th interscience conference on antimicrobial agents and chemotherapy. 2014.

20.

Yamazaki T, Desai A, Kowalski D. Pharmacokinetic (PK) interaction between isavuconazole (ISA) and a fixed-dose combination of lopinavir [LPV] 400 mg/ritonavir [RTV] 100 mg in healthy subjects (abstract no. 722). In: IDWeek. 2013.

21.

Townsend R, Yamazaki T, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of oral contraceptive with ethinyl estradiol and norethindrone in healthy subjects [abstract no. PII-088]. Clin Pharmacol Ther. 2014;95(Suppl 1):S90–1.

22.

Desai A, Zadeikis N, Howieson C, et al. Isavuconazole does not affect prednisolone pharmacokinetics in healthy subjects following coadministration of multiple dose isavuconazole. Clin Pharmacol Ther. 2013;93:S39.

23.

Desai A, Pearlman H, Yamazaki T, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP1A2 substrate caffeine and CYP2C8 substrate repaglinide in healthy subjects (abstract no. A-696). In: 54th interscience conference on antimicrobial agents and chemotherapy. 2014.

24.

Desai A, Yamazaki T, Lademacher C, et al. Effect of multiple doses of isavuconzole on the pharmacokinetics of methadone in healthy subjects (abstract no. R6335). In: American Association of Pharmaceutical Scientists annual meeting. 2013.

25.

Yamazaki T, Pearlman H, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate atorvastatin in healthy subjects (abstract no. A-449). In: 52nd interscience conference on antimicrobial agents and chemotherapy. 2012.

26.

Desai A, Yamazaki T, Lademacher C, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP2D6 substrate dextromethorphan in healthy subjects (abstract no. R6334). In: American Association of Pharmaceutical Scientists annual meeting. 2013.

27.

Desai A, Zadeikis N, Pearlman H. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate midazolam in healthy volunteers (abstract no. A-1936). In: 52nd interscience conference on antimicrobial agents and chemotherapy. 2012.

28.

Yamazaki T, Zadeikis N, Pearlman H, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of sirolimus in healthy subjects. Clin Pharmacol Ther. 2013;93:S114.

29.

Desai A, Zadeikis N, Pearlman H, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP3A4 substrate tacrolimus in healthy subjects. Clin Pharmacol Ther. 2013;93:S39–40.

30.

Desai A, Pearlman H, Yamazaki T, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of CYP2B6 substrate bupropion in healthy subjects (abstract no. A-450). In: 53rd interscience conference on antimicrobial agents and chemotherapy. 2013.

31.

Townsend R, Desai A, Howieson C, et al. Clinical considerations for coadministration of the novel antifungal isavuconazole with immunosuppressive agents (abstract no. P199). Transplant Int. 2013;26(Suppl 2):227.

32.

Desai A, Zadeikis N, Breese N, et al. Isavuconazole does not significantly affect the pharmacokinetics of p-glycoprotein substrate digoxin in healthy subjects. Clin Pharmacol Ther. 2013;93:S40.

33.

Desai A, Yamazaki T, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of metformin in healthy subjects (abstract no. PI-072). Clin Pharmacol Ther. 2014;95(Suupl 1):S41.

34.

Yamazaki T, Desai A, Kowalski D, et al. Effect of multiple doses of isavuconazole on the pharmacokinetics of methotrexate in healthy subjects (abstract no. PII-095). Clin Pharmacol Ther. 2014;95(Suppl 1):S93.

35.

Maertens J, Patterson T, Rahav G, et al. A phase 3 randomised, double-blind trial evaluating isavuconazole vs. voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other filamentous fungi (SECURE) (abstract no. O230a). In: 24th European Congress of Clinical Microbiology and Infectious Diseases. 2014.

36.

Thompson GR, Rendon A, Santos R, et al. Outcomes in patients with invasive fungal disease caused by dimorphic fungi treated with isavuconazole: experience from the VITAL trial (abstract no. M-1775). In: 54th Interscience Conference On Antimicrobial Agents And Chemotherapy. 2014.

37.

Queiroz-Telles F, Cornely OA, Perfect J, et al. Successful outcomes in patients with invasive fungal disease due to C. gattii and C. neoformans treated with isavuconazole: experience from the VITAL trial (abstract no. M-1773). In: 54th interscience conference on antimicrobial agents and chemotherapy. 2014.

38.

Viljoen J, Azie N, Schmitt-Hoffmann AH, et al. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother. 2015;59(3):1671–9.CrossRefPubMedCentralPubMed

39.

Cornely OA, Bohme A, Schmitt-Hoffmann A, et al. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59(4):2078–85.CrossRefPubMedCentralPubMed

40.

Basilea Pharmaceutica. Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study (media release). 2014. http://www.basilea.com.

Titel: Isavuconazonium: First Global Approval
verfasst von: Paul L. McCormack
Publikationsdatum: 01.05.2015
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 7/2015
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-015-0398-6

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2015

Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Vorapaxar: A Review of Its Use in the Long-Term Secondary Prevention of Atherothrombotic Events

Antisense Approach to Inflammatory Bowel Disease: Prospects and Challenges

Disease Modification in Epilepsy: From Animal Models to Clinical Applications

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status

Targeting High-Density Lipoproteins: Increasing De Novo Production Versus Decreasing Clearance